Navigation Links
Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
Date:5/23/2008

SAN DIEGO, May 23 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) today announced that its annual meeting of stockholders will be held on June 5, 2008 at 9:00 a.m. Pacific Time, at the San Diego Marriott Del Mar, 11966 El Camino Real, San Diego, California. The record date for stockholders entitled to vote at the annual meeting is April 10, 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

About Cardium

Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic and related indications. Cardium's lead product candidate, Generx(TM) (alferminogene tadenovec, Ad5FGF4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina. For more information about Cardium and its businesses, products and therapeutic candidates, please visit http://www.cardiumthx.com or view its 2007 Annual Report at http://www.cardiumthx.com/flash/pdf/CardiumAR07_Book_FINAL.pdf.

Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of patient temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more informatio
'/>"/>

SOURCE Cardium Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology technology :

1. Cardium Announces $5.3 Million Registered Direct Offering
2. Cardium Completes $5.3 Million Registered Direct Offering
3. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
4. Cardiums InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems
5. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
6. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
7. Cardium Reports on First Quarter 2008 Highlights and Financial Results
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...T, N.Y., Nov. 19 Dr. Mate Hidvegi,...responds to a press release issued on November 17 ...any for making false and self-serving statements a..., Dr. Hidvegi stated from his office in Budapest...rch on Avemar does not apply to AveULTRA, www.av...
(Date:11/19/2009)...MUNSTER, Germany, November 19 MONI...n November 16th, 2009 Flibanserin in the,indicatio...n Parkinson,s,disease for orphan drug status desig...Levodopa-induced dyskinesia is a complication of t...a serious burden to some of those,affected, since ...
(Date:11/19/2009)... VIENNA, Austria, November 19 AFFi...on one product candidate at an unexpectedly early,...s planned to enter into,Phase II clinical trial ea...ely follows the completion of two Phase I trials w...d its fast decision on the first interim,analysis ...
(Date:11/18/2009)...een,s University Belfast are developing new sensor...h will help in the fight against the threat of ter...el pads to ,swipe, an individual or crime scene to...ing instrument that can detect the presence of che...ter decisions to be made in response to terrorist ...
Breaking Biology Technology:American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor 2MONITORING FORCE GmbH Requests Acknowledgment of Flibanserin as "Orphan Drug" 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3New technology detects chemical weapons in seconds 2
...ces its focus on new Rapid-Fill ASF colored label ...cts at the 2008 American Society of Health-System ...on beginning today at the Orange County Convention... Dec. 8 Baxa Corporation is featuring its new Rap...y and Compliance Tools (PACT), Exacta-Mix Automate...
...Building on its flagship,suite of medication and i...y,launched the Pyxis(R) MedStation(R) 4000 and an ...provides hospitals with customized, actionable,rec... The Pyxis(R) MedStation(R) 4000 automated me...t can help hospitals increase the security of,high...
...ron alfa-2b) met its primary endpoint of non-infer...CHIEVE 2/3 trial in patients with genotypes 2 and ...ving 900-mcg Albuferon had comparable rates of ser...continuations due to adverse events, vs. peginterf...man Genome Sciences, Inc. (Nasdaq: HGSI ) today ...
Other Biology Technology:Baxa Features Rapid-Fill(TM) Colored Labels, PACT(TM) Products, Exacta-Mix(TM) 2400 Compounders and Abacus(TM) Software at the ASHP Mid-Year Clinical Meeting 2Baxa Features Rapid-Fill(TM) Colored Labels, PACT(TM) Products, Exacta-Mix(TM) 2400 Compounders and Abacus(TM) Software at the ASHP Mid-Year Clinical Meeting 3Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 2Cardinal Health Launches Pyxis(R) MedStation(R) 4000; Introduces Industry-First Service to Interpret Dispensing and Infusion Data 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 2Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 3Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 4Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 5Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 6Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 7Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 8Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C 9
(Date:11/22/2009)... A butterfly,s proboscis looks like a straw -- lon...ore like a paper towel, according to Konstantin Ko... tricks of this piece of insect anatomy to make sm...ls. , Kornev will present his work next week at ...ociety,s (APS) Division of Fluid Dynamics will tak...
(Date:11/20/2009)...ovember 2009 issue of the journal GENETICS ( htt...ly of genes (1-aminocyclopropane-1-carboxylate syn...n of ethylene. This gas affects many aspects of pl...ndation for future genetic manipulation that could...d thrive in difficult terrain, increase yields, an...
(Date:11/20/2009)...ntists from the Marine Biogeochemistry and Geology...oratory (NRL) organized and led a team of universi...on to initiate methane hydrate exploration in the ...f sediment contribution to Arctic climate change. ...a as a research platform, three cross-shelf transe...
Breaking Biology News(10 mins):It's a gas: New discovery may lead to heartier, high-yielding plants 2International expedition investigates climate change, alternative fuels in Arctic 2Switch program increases kids healthy eating reduces screen time 57952 1Switch program increases kids healthy eating reduces screen time 57952 2InfoLogix Selected by Albert Einstein Healthcare Network for eLearning Modules to Support EMR Implementation 57951 1InfoLogix Selected by Albert Einstein Healthcare Network for eLearning Modules to Support EMR Implementation 57951 2InfoLogix Selected by Albert Einstein Healthcare Network for eLearning Modules to Support EMR Implementation 57951 3Moroney 26 Gill Inc Launches New Website 57946 1
...ng calories leads to a longer life, scientists hav...rst time that such a diet also can maintain physic...y inevitable progression to physical disability an...odel of life-time caloric restriction, showed that...h expresses inflammatory factors that in humans ca...
...ern Reserve Universitys School of Medicine have pu...e discovery with a natural product derived from th... suggest a broad set of applications in various jo... osteoarthritis and irritable bowel syndrome., The...om a rainforest tree called Croton palanostigma, w...
...uate class, being given a dissertation by one of y.... , This was the experience of successive cohort...ondon,s) Department of Science and Technology Stud...vative approach to teaching is a full-blown academ...ociety for the History of Science (BSHS). , The b...
Other Biology News:Severely restricted diet linked to physical fitness into old age 2Natural product discovery by Cleveland medical researchers blocks tissue destruction 2
Rabbit Anti-TWIK-1 Antibody, Unconjugated from CHEMICON
Anti-Bunyavirus (G1) Monoclonal Antibody, Unconjugated, Clone 8C2.1 from CHEMICON
Rabbit Anti-BI-1 Polyclonal Antibody, Unconjugated from BioVision
Capped Xef-1 RNA 0.05 ml from Ambion
Biology Products: